Physician profile
Nicolas A Chronos
NPI 1427057165
$912,351.81
in general payments reported to CMS, 2019-2025
42 companies · $18K in 2025
The $18K reported for 2025 was more than what 96% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $472 · 2020: $376 · 2021: $1,299 · 2022: $429 · 2023: $1,066 · 2024: $891K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $907K · Food and Beverage: $2,612.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $907,163.34 |
| Food and Beverage | $2,611.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $907,417.31 | 2023-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Novartis Pharmaceuticals Corporation | $1,092.66 | 2019-2025 | |
| Novo Nordisk INC | $458.33 | 2020-2025 | Ozempic, Wegovy, Rybelsus |
| Abbott Laboratories | $372.08 | 2023-2025 | Mitraclip, Freestyle Libre 3, Freestyle Libre 2 |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $333.71 | 2019-2024 | Lifevest |
| Astrazeneca Pharmaceuticals Lp | $250.12 | 2019-2025 | Farxiga, Airsupra |
| Janssen Pharmaceuticals, INC | $216.92 | 2019-2024 | Xarelto |
| Cvrx, INC. | $214.95 | 2024 | Barostim Neo System |
| Dexcom, INC. | $210.45 | 2023-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $209.25 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $207.80 | 2019-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $178.08 | 2021-2024 | Verquvo, Belsomra |
| Impulse Dynamics (USA) INC. | $174.46 | 2023-2024 | Optimizer, Optimizer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.88 | 2019-2025 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $113.48 | 2020-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $113.24 | 2022-2025 | |
| Mylan Specialty L.P. | $109.75 | 2021-2024 | Yupelri |
| Amarin Pharma, INC. | $92.50 | 2019-2020 | |
| Biotronik INC. | $70.70 | 2023 | Biomonitor |
| Lilly USA, LLC | $62.82 | 2023 | Mounjaro |
| Esperion Therapeutics, INC. | $45.20 | 2024-2025 | Nexletol |
| Senseonics, Incorporated | $36.17 | 2025 | Eversense |
| Beckman Coulter, INC. | $28.14 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.27 | 2023 | Xifaxan |
| Inspire Medical Systems, INC. | $23.55 | 2024 | Inspire |
| Corcept Therapeutics | $22.60 | 2025 | Korlym |
| Scpharmaceuticals INC. | $20.99 | 2025 | |
| Ascensia Diabetes Care US INC. | $19.62 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $15.48 | 2024 | Arcalyst |
| Boston Scientific Corporation | $15.15 | 2024 | Watchman Access System |
| Idorsia Pharmaceuticals US INC | $14.16 | 2023 | Quviviq |
| Abbvie INC. | $11.99 | 2022 |
10 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$370,996.42 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicolas Chronos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.